APO Research
Talk to an analyst

APO RESEARCH · REPORT

Acute Vulvovaginal Candidiasis Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Acute Vulvovaginal Candidiasis Treatment Industry Growth and Trends Forecast to 2032

20 December 2025122 pages

Choose your research edition.

Industry ResearchAcute Vulvovaginal Candidiasis Treatment Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Vulvovaginal Candidiasis Treatment Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Acute Vulvovaginal Candidiasis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Vulvovaginal Candidiasis Treatment Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Vulvovaginal Candidiasis Treatment Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

According to APO Research, the global Acute Vulvovaginal Candidiasis Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Acute Vulvovaginal Candidiasis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Acute Vulvovaginal Candidiasis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Acute Vulvovaginal Candidiasis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Acute Vulvovaginal Candidiasis Treatment market include Sandoz International GmbH, Novartis AG, Mylan N.V., Pfizer, Inc., Bayer AG., Scynexis, Inc, Phathom Pharmaceutical, Inc, Pacgen Life Science Corporation and NovaDigm Therapeutics, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Acute Vulvovaginal Candidiasis Treatment market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Acute Vulvovaginal Candidiasis Treatment market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Acute Vulvovaginal Candidiasis Treatment market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Acute Vulvovaginal Candidiasis Treatment.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Acute Vulvovaginal Candidiasis Treatment market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Acute Vulvovaginal Candidiasis Treatment Market by Company

Sandoz International GmbH

Novartis AG

Mylan N.V.

Pfizer, Inc.

Bayer AG.

Scynexis, Inc

Phathom Pharmaceutical, Inc

Pacgen Life Science Corporation

NovaDigm Therapeutics, Inc

Mycovia Pharmaceuticals, Inc

Lupin

Grupo Ferrer Internacional, S.A

Cidara Therapeutics, Inc

Cadila Pharmaceuticals

Bristol-Myers Squibb Company

Basilea Pharmaceutica Ltd

Astellas Pharma Inc

Amplyx Pharmaceuticals Inc

Amneal Pharmaceuticals LLC

Accord Healthcare Ltd

Acute Vulvovaginal Candidiasis Treatment Segment by Type

Nystatin

Ketoconazole

Terconazole

Terbinafine

Clotrimazole

Fluconazole

Others

Acute Vulvovaginal Candidiasis Treatment Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Acute Vulvovaginal Candidiasis Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Vulvovaginal Candidiasis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Vulvovaginal Candidiasis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Vulvovaginal Candidiasis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Acute Vulvovaginal Candidiasis Treatment companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Acute Vulvovaginal Candidiasis Treatment Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2021-2026) Table 4. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2027-2032) Table 6. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Acute Vulvovaginal Candidiasis Treatment Market Size Share by Type (2021-2026) Table 9. Global Acute Vulvovaginal Candidiasis Treatment Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Acute Vulvovaginal Candidiasis Treatment Market Size Share Forecasted by Type (2027-2032) Table 11. North America Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Acute Vulvovaginal Candidiasis Treatment Market Size Share by Application (2021-2026) Table 24. Global Acute Vulvovaginal Candidiasis Treatment Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Acute Vulvovaginal Candidiasis Treatment Market Size Share Forecasted by Application (2027-2032) Table 26. North America Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Acute Vulvovaginal Candidiasis Treatment Industry Trends Table 37. Acute Vulvovaginal Candidiasis Treatment Industry Drivers Table 38. Acute Vulvovaginal Candidiasis Treatment Industry Opportunities and Challenges Table 39. Acute Vulvovaginal Candidiasis Treatment Industry Restraints Table 40. Global Acute Vulvovaginal Candidiasis Treatment Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Company (2021-2026) Table 42. Global Acute Vulvovaginal Candidiasis Treatment Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Acute Vulvovaginal Candidiasis Treatment Key Company Headquarters & Area Served Table 44. Global Acute Vulvovaginal Candidiasis Treatment Company, Product Type & Application Table 45. Global Acute Vulvovaginal Candidiasis Treatment Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Acute Vulvovaginal Candidiasis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Sandoz International GmbH Company Information Table 49. Sandoz International GmbH Business Overview Table 50. Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 52. Sandoz International GmbH Recent Development Table 53. Novartis AG Company Information Table 54. Novartis AG Business Overview Table 55. Novartis AG Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Novartis AG Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 57. Novartis AG Recent Development Table 58. Mylan N.V. Company Information Table 59. Mylan N.V. Business Overview Table 60. Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 62. Mylan N.V. Recent Development Table 63. Pfizer, Inc. Company Information Table 64. Pfizer, Inc. Business Overview Table 65. Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 67. Pfizer, Inc. Recent Development Table 68. Bayer AG. Company Information Table 69. Bayer AG. Business Overview Table 70. Bayer AG. Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Bayer AG. Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 72. Bayer AG. Recent Development Table 73. Scynexis, Inc Company Information Table 74. Scynexis, Inc Business Overview Table 75. Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 77. Scynexis, Inc Recent Development Table 78. Phathom Pharmaceutical, Inc Company Information Table 79. Phathom Pharmaceutical, Inc Business Overview Table 80. Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 82. Phathom Pharmaceutical, Inc Recent Development Table 83. Pacgen Life Science Corporation Company Information Table 84. Pacgen Life Science Corporation Business Overview Table 85. Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 87. Pacgen Life Science Corporation Recent Development Table 88. NovaDigm Therapeutics, Inc Company Information Table 89. NovaDigm Therapeutics, Inc Business Overview Table 90. NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 92. NovaDigm Therapeutics, Inc Recent Development Table 93. Mycovia Pharmaceuticals, Inc Company Information Table 94. Mycovia Pharmaceuticals, Inc Business Overview Table 95. Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 97. Mycovia Pharmaceuticals, Inc Recent Development Table 98. Lupin Company Information Table 99. Lupin Business Overview Table 100. Lupin Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Lupin Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 102. Lupin Recent Development Table 103. Grupo Ferrer Internacional, S.A Company Information Table 104. Grupo Ferrer Internacional, S.A Business Overview Table 105. Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 107. Grupo Ferrer Internacional, S.A Recent Development Table 108. Cidara Therapeutics, Inc Company Information Table 109. Cidara Therapeutics, Inc Business Overview Table 110. Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 112. Cidara Therapeutics, Inc Recent Development Table 113. Cadila Pharmaceuticals Company Information Table 114. Cadila Pharmaceuticals Business Overview Table 115. Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 117. Cadila Pharmaceuticals Recent Development Table 118. Bristol-Myers Squibb Company Company Information Table 119. Bristol-Myers Squibb Company Business Overview Table 120. Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 122. Bristol-Myers Squibb Company Recent Development Table 123. Basilea Pharmaceutica Ltd Company Information Table 124. Basilea Pharmaceutica Ltd Business Overview Table 125. Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 127. Basilea Pharmaceutica Ltd Recent Development Table 128. Astellas Pharma Inc Company Information Table 129. Astellas Pharma Inc Business Overview Table 130. Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 132. Astellas Pharma Inc Recent Development Table 133. Amplyx Pharmaceuticals Inc Company Information Table 134. Amplyx Pharmaceuticals Inc Business Overview Table 135. Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 137. Amplyx Pharmaceuticals Inc Recent Development Table 138. Amneal Pharmaceuticals LLC Company Information Table 139. Amneal Pharmaceuticals LLC Business Overview Table 140. Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 142. Amneal Pharmaceuticals LLC Recent Development Table 143. Accord Healthcare Ltd Company Information Table 144. Accord Healthcare Ltd Business Overview Table 145. Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 147. Accord Healthcare Ltd Recent Development Table 148. North America Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026) & (US$ Million) Table 150. North America Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2026) Table 151. North America Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. North America Acute Vulvovaginal Candidiasis Treatment Market Share Forecast by Country (2027-2032) Table 153. Europe Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026) & (US$ Million) Table 155. Europe Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2026) Table 156. Europe Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Europe Acute Vulvovaginal Candidiasis Treatment Market Share Forecast by Country (2027-2032) Table 158. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026) & (US$ Million) Table 160. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2026) Table 161. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Share Forecast by Country (2027-2032) Table 163. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026) & (US$ Million) Table 165. Latin America Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2026) Table 166. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Latin America Acute Vulvovaginal Candidiasis Treatment Market Share Forecast by Country (2027-2032) Table 168. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026) & (US$ Million) Table 170. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2026) Table 171. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Share Forecast by Country (2027-2032) Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Acute Vulvovaginal Candidiasis Treatment Product Image Figure 3. Global Acute Vulvovaginal Candidiasis Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 5. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region: 2025 VS 2032 Figure 6. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2021-2032) Figure 7. North America Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Nystatin Image Figure 13. Global Nystatin Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Ketoconazole Image Figure 15. Global Ketoconazole Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Terconazole Image Figure 17. Global Terconazole Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Terbinafine Image Figure 19. Global Terbinafine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Clotrimazole Image Figure 21. Global Clotrimazole Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Fluconazole Image Figure 23. Global Fluconazole Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Others Image Figure 25. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 26. Global Acute Vulvovaginal Candidiasis Treatment Market Size Overview by Type (2021-2032) & (US$ Million) Figure 27. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Type 2025 VS 2032 Figure 28. North America Acute Vulvovaginal Candidiasis Treatment Market Size Share by Type (2021-2032) Figure 29. Europe Acute Vulvovaginal Candidiasis Treatment Market Size Share by Type (2021-2032) Figure 30. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Share by Type (2021-2032) Figure 31. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size Share by Type (2021-2032) Figure 32. Middle East and Africa Acute Vulvovaginal Candidiasis Treatment Market Size Share by Type (2021-2032) Figure 33. Retail Pharmacies Image Figure 34. Global Retail Pharmacies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Online Pharmacies Image Figure 36. Global Online Pharmacies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Hospital Pharmacies Image Figure 38. Global Hospital Pharmacies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Global Acute Vulvovaginal Candidiasis Treatment Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Application 2025 VS 2032 Figure 41. North America Acute Vulvovaginal Candidiasis Treatment Market Size Share by Application (2021-2032) Figure 42. Europe Acute Vulvovaginal Candidiasis Treatment Market Size Share by Application (2021-2032) Figure 43. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Share by Application (2021-2032) Figure 44. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size Share by Application (2021-2032) Figure 45. Middle East and Africa Acute Vulvovaginal Candidiasis Treatment Market Size Share by Application (2021-2032) Figure 46. Global Top 5 and 10 Acute Vulvovaginal Candidiasis Treatment Players Market Share by Revenue in 2025 Figure 47. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 48. North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. North America Acute Vulvovaginal Candidiasis Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. North America Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032) Figure 51. Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Acute Vulvovaginal Candidiasis Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032) Figure 54. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032) Figure 57. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Acute Vulvovaginal Candidiasis Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032) Figure 60. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 62. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032) Figure 63. Years Considered Figure 64. Research Process Figure 65. Key Executives Interviewed

Scope & coverage.

Types
  • Nystatin
  • Ketoconazole
  • Terconazole
  • Terbinafine
  • Clotrimazole
  • Fluconazole
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Sandoz International GmbH
  • Novartis AG
  • Mylan N.V.
  • Pfizer, Inc.
  • Bayer AG.
  • Scynexis, Inc
  • Phathom Pharmaceutical, Inc
  • Pacgen Life Science Corporation
  • NovaDigm Therapeutics, Inc
  • Mycovia Pharmaceuticals, Inc
  • Lupin
  • Grupo Ferrer Internacional, S.A
  • Cidara Therapeutics, Inc
  • Cadila Pharmaceuticals
  • Bristol-Myers Squibb Company
  • Basilea Pharmaceutica Ltd
  • Astellas Pharma Inc
  • Amplyx Pharmaceuticals Inc
  • Amneal Pharmaceuticals LLC
  • Accord Healthcare Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Acute Vulvovaginal Candidiasis Treatment Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2021-2032)
  5. 1.4.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2021-2026)
  6. 1.4.2 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2027-2032)
  7. 1.5 Key Regions Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032)
  8. 1.5.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (2021-2032)
2 Acute Vulvovaginal Candidiasis Treatment Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Nystatin
  3. 2.1.2 Ketoconazole
  4. 2.1.3 Terconazole
  5. 2.1.4 Terbinafine
  6. 2.1.5 Clotrimazole
  7. 2.1.6 Fluconazole
  8. 2.1.7 Others
  9. 2.2 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Type
  10. 2.2.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size Overview by Type (2021-2032)
  11. 2.2.2 Global Acute Vulvovaginal Candidiasis Treatment Historic Market Size Review by Type (2021-2026)
  12. 2.2.3 Global Acute Vulvovaginal Candidiasis Treatment Market Size Forecasted by Type (2027-2032)
  13. 2.3 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Regions
  14. 2.3.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Type (2021-2026)
  15. 2.3.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Type (2021-2026)
  16. 2.3.3 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Type (2021-2026)
  17. 2.3.4 South America Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Type (2021-2026)
  18. 2.3.5 Middle East and Africa Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Type (2021-2026)
3 Acute Vulvovaginal Candidiasis Treatment Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Retail Pharmacies
  3. 3.1.2 Online Pharmacies
  4. 3.1.3 Hospital Pharmacies
  5. 3.2 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application
  6. 3.2.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Acute Vulvovaginal Candidiasis Treatment Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Acute Vulvovaginal Candidiasis Treatment Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Regions
  10. 3.3.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Acute Vulvovaginal Candidiasis Treatment Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Acute Vulvovaginal Candidiasis Treatment Industry Trends
  2. 4.2 Acute Vulvovaginal Candidiasis Treatment Industry Drivers
  3. 4.3 Acute Vulvovaginal Candidiasis Treatment Industry Opportunities and Challenges
  4. 4.4 Acute Vulvovaginal Candidiasis Treatment Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Acute Vulvovaginal Candidiasis Treatment Revenue (2021-2026)
  2. 5.2 Global Acute Vulvovaginal Candidiasis Treatment Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Acute Vulvovaginal Candidiasis Treatment Key Company Headquarters & Area Served
  4. 5.4 Global Acute Vulvovaginal Candidiasis Treatment Company, Product Type & Application
  5. 5.5 Global Acute Vulvovaginal Candidiasis Treatment Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Acute Vulvovaginal Candidiasis Treatment Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Acute Vulvovaginal Candidiasis Treatment Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Acute Vulvovaginal Candidiasis Treatment Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Sandoz International GmbH
  2. 6.1.1 Sandoz International GmbH Company Information
  3. 6.1.2 Sandoz International GmbH Business Overview
  4. 6.1.3 Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  6. 6.1.5 Sandoz International GmbH Recent Developments
  7. 6.2 Novartis AG
  8. 6.2.1 Novartis AG Company Information
  9. 6.2.2 Novartis AG Business Overview
  10. 6.2.3 Novartis AG Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Novartis AG Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  12. 6.2.5 Novartis AG Recent Developments
  13. 6.3 Mylan N.V.
  14. 6.3.1 Mylan N.V. Company Information
  15. 6.3.2 Mylan N.V. Business Overview
  16. 6.3.3 Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  18. 6.3.5 Mylan N.V. Recent Developments
  19. 6.4 Pfizer, Inc.
  20. 6.4.1 Pfizer, Inc. Company Information
  21. 6.4.2 Pfizer, Inc. Business Overview
  22. 6.4.3 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  24. 6.4.5 Pfizer, Inc. Recent Developments
  25. 6.5 Bayer AG.
  26. 6.5.1 Bayer AG. Company Information
  27. 6.5.2 Bayer AG. Business Overview
  28. 6.5.3 Bayer AG. Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Bayer AG. Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  30. 6.5.5 Bayer AG. Recent Developments
  31. 6.6 Scynexis, Inc
  32. 6.6.1 Scynexis, Inc Company Information
  33. 6.6.2 Scynexis, Inc Business Overview
  34. 6.6.3 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  36. 6.6.5 Scynexis, Inc Recent Developments
  37. 6.7 Phathom Pharmaceutical, Inc
  38. 6.7.1 Phathom Pharmaceutical, Inc Company Information
  39. 6.7.2 Phathom Pharmaceutical, Inc Business Overview
  40. 6.7.3 Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  42. 6.7.5 Phathom Pharmaceutical, Inc Recent Developments
  43. 6.8 Pacgen Life Science Corporation
  44. 6.8.1 Pacgen Life Science Corporation Company Information
  45. 6.8.2 Pacgen Life Science Corporation Business Overview
  46. 6.8.3 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  48. 6.8.5 Pacgen Life Science Corporation Recent Developments
  49. 6.9 NovaDigm Therapeutics, Inc
  50. 6.9.1 NovaDigm Therapeutics, Inc Company Information
  51. 6.9.2 NovaDigm Therapeutics, Inc Business Overview
  52. 6.9.3 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  54. 6.9.5 NovaDigm Therapeutics, Inc Recent Developments
  55. 6.10 Mycovia Pharmaceuticals, Inc
  56. 6.10.1 Mycovia Pharmaceuticals, Inc Company Information
  57. 6.10.2 Mycovia Pharmaceuticals, Inc Business Overview
  58. 6.10.3 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  60. 6.10.5 Mycovia Pharmaceuticals, Inc Recent Developments
  61. 6.11 Lupin
  62. 6.11.1 Lupin Company Information
  63. 6.11.2 Lupin Business Overview
  64. 6.11.3 Lupin Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Lupin Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  66. 6.11.5 Lupin Recent Developments
  67. 6.12 Grupo Ferrer Internacional, S.A
  68. 6.12.1 Grupo Ferrer Internacional, S.A Company Information
  69. 6.12.2 Grupo Ferrer Internacional, S.A Business Overview
  70. 6.12.3 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  72. 6.12.5 Grupo Ferrer Internacional, S.A Recent Developments
  73. 6.13 Cidara Therapeutics, Inc
  74. 6.13.1 Cidara Therapeutics, Inc Company Information
  75. 6.13.2 Cidara Therapeutics, Inc Business Overview
  76. 6.13.3 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  78. 6.13.5 Cidara Therapeutics, Inc Recent Developments
  79. 6.14 Cadila Pharmaceuticals
  80. 6.14.1 Cadila Pharmaceuticals Company Information
  81. 6.14.2 Cadila Pharmaceuticals Business Overview
  82. 6.14.3 Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  84. 6.14.5 Cadila Pharmaceuticals Recent Developments
  85. 6.15 Bristol-Myers Squibb Company
  86. 6.15.1 Bristol-Myers Squibb Company Company Information
  87. 6.15.2 Bristol-Myers Squibb Company Business Overview
  88. 6.15.3 Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  90. 6.15.5 Bristol-Myers Squibb Company Recent Developments
  91. 6.16 Basilea Pharmaceutica Ltd
  92. 6.16.1 Basilea Pharmaceutica Ltd Company Information
  93. 6.16.2 Basilea Pharmaceutica Ltd Business Overview
  94. 6.16.3 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  96. 6.16.5 Basilea Pharmaceutica Ltd Recent Developments
  97. 6.17 Astellas Pharma Inc
  98. 6.17.1 Astellas Pharma Inc Company Information
  99. 6.17.2 Astellas Pharma Inc Business Overview
  100. 6.17.3 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  102. 6.17.5 Astellas Pharma Inc Recent Developments
  103. 6.18 Amplyx Pharmaceuticals Inc
  104. 6.18.1 Amplyx Pharmaceuticals Inc Company Information
  105. 6.18.2 Amplyx Pharmaceuticals Inc Business Overview
  106. 6.18.3 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  108. 6.18.5 Amplyx Pharmaceuticals Inc Recent Developments
  109. 6.19 Amneal Pharmaceuticals LLC
  110. 6.19.1 Amneal Pharmaceuticals LLC Company Information
  111. 6.19.2 Amneal Pharmaceuticals LLC Business Overview
  112. 6.19.3 Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  114. 6.19.5 Amneal Pharmaceuticals LLC Recent Developments
  115. 6.20 Accord Healthcare Ltd
  116. 6.20.1 Accord Healthcare Ltd Company Information
  117. 6.20.2 Accord Healthcare Ltd Business Overview
  118. 6.20.3 Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  120. 6.20.5 Accord Healthcare Ltd Recent Developments
7 North America
  1. 7.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026)
  3. 7.3 North America Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026)
  3. 8.3 Europe Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026)
  3. 10.3 South America Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst